VOYA Investment Management
TBPH icon

VOYA Investment Management’s Theravance Biopharma TBPH Stock Holding History

VOYA Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,484
Closed -$316K – 2559
2026
Q1 		$316K Buy
+19,484
New +$345K ﹤0.01% 1925
2025
Q3 		– Sell
-11,593
Closed -$128K – 2640
2025
Q2 		$128K Hold
11,593
– – ﹤0.01% 2429
2025
Q1 		$104K Sell
11,593
-1,509
-12% -$14K ﹤0.01% 2428
2024
Q4 		$123K Sell
13,102
-801
-6% -$7.29K ﹤0.01% 2528
2024
Q3 		$112K Sell
13,903
-2,979
-18% -$25.8K ﹤0.01% 2635
2024
Q2 		$143K Sell
16,882
-1,082
-6% -$9.77K ﹤0.01% 2571
2024
Q1 		$161K Sell
17,964
-6,072
-25% -$56.3K ﹤0.01% 2521
2023
Q4 		$270K Sell
24,036
-2,488
-9% -$25K ﹤0.01% 2412
2023
Q3 		$229K Hold
26,524
– – ﹤0.01% 2470
2023
Q2 		$275K Buy
26,524
+575
+2% +$6.35K ﹤0.01% 2421
2023
Q1 		$282K Hold
25,949
– – ﹤0.01% 2361
2022
Q4 		$291K Hold
25,949
– – ﹤0.01% 2352
2022
Q3 		$263K Buy
25,949
+1,408
+6% +$13.2K ﹤0.01% 2432
2022
Q2 		$222K Sell
24,541
-16,395
-40% -$151K ﹤0.01% 2338
2022
Q1 		$391K Sell
40,936
-262
-0.6% -$2.57K ﹤0.01% 2043
2021
Q4 		$455K Buy
41,198
+19,969
+94% +$174K ﹤0.01% 2079
2021
Q3 		$157K Buy
21,229
+228
+1% +$2.55K ﹤0.01% 2640
2021
Q2 		$305K Sell
21,001
-614
-3% -$11.5K ﹤0.01% 2368
2021
Q1 		$441K Buy
21,615
+1,610
+8% +$30.6K ﹤0.01% 2100
2020
Q4 		$355K Buy
20,005
+3,062
+18% +$55K ﹤0.01% 2112
2020
Q3 		$251K Hold
16,943
– – ﹤0.01% 2036
2020
Q2 		$356K Sell
16,943
-6,942
-29% -$178K ﹤0.01% 1875
2020
Q1 		$552K Buy
23,885
+2,653
+12% +$66.4K ﹤0.01% 1569
2019
Q4 		$550K Buy
21,232
+2,402
+13% +$46.7K ﹤0.01% 1834
2019
Q3 		$367K Hold
18,830
– – ﹤0.01% 1933
2019
Q2 		$307K Buy
18,830
+896
+5% +$18.2K ﹤0.01% 2075
2019
Q1 		$407K Sell
17,934
-583
-3% -$14.8K ﹤0.01% 1890
2018
Q4 		$474K Buy
18,517
+942
+5% +$25.4K ﹤0.01% 1744
2018
Q3 		$574K Hold
17,575
– – ﹤0.01% 1766
2018
Q2 		$399K Sell
17,575
-1,375
-7% -$32.6K ﹤0.01% 1965
2018
Q1 		$460K Hold
18,950
– – ﹤0.01% 1855
2017
Q4 		$529K Hold
18,950
– – ﹤0.01% 1807
2017
Q3 		$649K Hold
18,950
– – ﹤0.01% 1693
2017
Q2 		$755K Buy
18,950
+4,067
+27% +$156K ﹤0.01% 1577
2017
Q1 		$548K Hold
14,883
– – ﹤0.01% 1667
2016
Q4 		$474K Hold
14,883
– – ﹤0.01% 1770
2016
Q3 		$539K Hold
14,883
– – ﹤0.01% 1679
2016
Q2 		$338K Buy
14,883
+2,461
+20% +$53.1K ﹤0.01% 1956
2016
Q1 		$234K Hold
12,422
– – ﹤0.01% 2139
2015
Q4 		$204K Hold
12,422
– – ﹤0.01% 2263
2015
Q3 		$137K Hold
12,422
– – ﹤0.01% 2403
2015
Q2 		$162K Hold
12,422
– – ﹤0.01% 2549
2015
Q1 		$216K Hold
12,422
– – ﹤0.01% 2398
2014
Q4 		$185K Hold
12,422
– – ﹤0.01% 2501
2014
Q3 		$286K Sell
12,422
-82
-0.7% -$2.38K ﹤0.01% 2291
2014
Q2 		$399K Buy
+12,504
New +$376K ﹤0.01% 2146

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

VOYA Investment Management's TBPH Position: Q2 2026 in Review

VOYA Investment Management sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 19,484 shares — an estimated $316K sold.

VOYA Investment Management first reported a position in TBPH in Q2 2014 and held it in 46 quarters. The position peaked at $755K in Q2 2017. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • VOYA Investment Management reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • VOYA Investment Management sold 19,484 Theravance Biopharma shares in Q2 2026, an estimated $316K.
  • VOYA Investment Management first reported a position in Theravance Biopharma in Q2 2014 and held it in 46 quarters.
  • VOYA Investment Management's Theravance Biopharma position peaked at $755K in Q2 2017.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.